Introduction
When analyzing the market and price projections for a specific drug, understanding the National Drug Code (NDC) and its associated data is crucial. Here, we will focus on the drug identified by the NDC 00378-2245, which corresponds to Imatinib Mesylate 100 MG tablets.
Drug Overview
Imatinib Mesylate, commonly known by its brand name Gleevec, is a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)[5].
Historical Price Trends
To understand the price projections, it is essential to look at the historical price trends of Imatinib Mesylate.
| Date |
Price/Unit ($) |
| 2024-12-18 |
0.66780 |
| 2024-11-20 |
0.64236 |
| 2024-10-23 |
0.54917 |
| 2024-09-18 |
0.50016 |
| 2024-08-21 |
0.53612 |
| 2024-07-17 |
0.49119 |
| 2024-06-19 |
0.40760 |
From the data, it is clear that the price per unit of Imatinib Mesylate has fluctuated over the past year, with a general trend of slight increases and decreases[1].
Market Factors Influencing Price
Several market factors can influence the price of pharmaceuticals like Imatinib Mesylate:
Drug Price Inflation
According to Vizient's summer Pharmacy Market Outlook, the overall drug price inflation rate for pharmaceuticals in 2025 is projected to be 3.81%. This inflation rate is driven by factors such as the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies[2].
Expanding Indications
The expansion of indications for existing drugs can significantly impact their market demand and pricing. For example, GLP-1 agents like semaglutide have seen a 77% increase in spend due to their approval for reducing the risk of major adverse cardiovascular events in overweight or obese adults with established cardiovascular disease[2].
Generic Competition
The patent expiration of blockbuster drugs can lead to increased generic competition, which can drive prices down. However, for Imatinib Mesylate, generic versions have already been available, and the price fluctuations observed are more related to market dynamics rather than new generic entries[4].
Future Price Projections
Given the current trends and market factors:
Inflation Impact
With an expected drug price inflation rate of 3.81% in 2025, it is likely that the price of Imatinib Mesylate will see a slight increase. However, this increase will be moderate and in line with the overall pharmaceutical market inflation.
Market Demand
The demand for Imatinib Mesylate is expected to remain stable due to its established use in treating CML and GIST. There are no significant changes in the treatment protocols or new competitors that would drastically alter its market position.
Pricing Strategy
Pharmaceutical companies often adjust prices based on market conditions, regulatory changes, and competitive pressures. Given the stable demand and moderate inflation, the price of Imatinib Mesylate is likely to see minor adjustments rather than significant hikes.
Industry Trends
Several broader industry trends will also influence the pharmaceutical market:
Personalization and Prevention
The pharmaceutical industry is moving towards more personalized and preventive care. While this trend is more relevant to new drug developments, it underscores the evolving landscape in which existing drugs like Imatinib Mesylate operate[3].
Regulatory Changes
Policy changes and regulatory updates can impact drug pricing. For instance, changes in health policies, tariffs, and M&A oversight can influence the overall profitability and pricing strategies of pharmaceutical companies[3].
Conclusion
The price of Imatinib Mesylate, identified by the NDC 00378-2245, is expected to see moderate increases in line with the projected 3.81% drug price inflation rate for 2025. The stable demand for this drug, coupled with the absence of significant new competitors or patent expirations, suggests that price fluctuations will be minimal.
Key Takeaways
- Historical Price Trends: The price of Imatinib Mesylate has shown slight fluctuations over the past year.
- Market Factors: Drug price inflation, expanding indications of other drugs, and generic competition are key factors influencing prices.
- Future Projections: Moderate price increases are expected due to overall market inflation.
- Industry Trends: Personalization, prevention, and regulatory changes are shaping the pharmaceutical industry.
FAQs
Q: What is the current price of Imatinib Mesylate 100 MG tablets?
A: As of December 18, 2024, the price per unit is $0.66780[1].
Q: What is the projected drug price inflation rate for 2025?
A: The projected drug price inflation rate for 2025 is 3.81% according to Vizient's summer Pharmacy Market Outlook[2].
Q: How does the expansion of indications for other drugs affect Imatinib Mesylate?
A: The expansion of indications for other drugs, such as GLP-1 agents, does not directly impact the price of Imatinib Mesylate but reflects broader market trends that could influence pricing strategies[2].
Q: Are there any significant changes in the patent status of Imatinib Mesylate?
A: Imatinib Mesylate has already seen the entry of generic versions, so patent expirations are not a current factor influencing its price[4].
Q: How do industry trends like personalization and prevention affect existing drugs?
A: While these trends are more relevant to new drug developments, they indicate an evolving healthcare landscape that could influence future pricing and market strategies for existing drugs[3].
Sources
- DrugPatentWatch, "Latest drug prices and trends for NDC 00378-2245".
- Vizient Inc., "Vizient projects drug price inflation at 3.81%".
- PwC, "Pharma industry trends: PwC".
- Drug Development, "NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025".
- FDA, "National Drug Code Directory".
